MedTrace Logo

MRD-positive AML Clinical Study

NCT07131059 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-08-20

No results posted yet for this study

Summary

This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.

Conditions

  • AML, Adult

Interventions

DRUG

Ivosidenib

500mg d1-28

DRUG

Gilteritinib

120mg d1-28

DRUG

Venetoclax

400mg d1-21 ; 400mg d1-7;400mg d1-28; 600mg d1-21

DRUG

Avapritinib

200mg d1-28.

DRUG

Daunorubicin

45mg/m2/d d1-2;

DRUG

Cytarabine

100mg/m2/d d1-5

DRUG

Idarubicin

10mg/m2/d d1-2

DRUG

MTZ

8mg/m2/d d1-2

DRUG

HHT

2mg/m2/d d1-5

DRUG

Azacitidine

75mgd/m2 d1-7.

Sponsors & Collaborators

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Principal Investigators

  • Huui Wei, doctor · Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-11
Primary Completion
2026-05-10
Completion
2028-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07131059 on ClinicalTrials.gov